Sun Nelson
Known title: See RemarksCIK: 0002045377
Sun Nelson's purchase track record
How the stock did after each of Sun Nelson's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since February 14, 2025
Stock higher 6 months later
0%
3 months: 33%
Median 6-month return
-26.8%
3 months: -25.6%
Beat the S&P 500
0%
median -30.9% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/11/2025 | AARD | $43K | -66.3% | -76.7% | +7.1% |
| 9/9/2025 | AARD | $48K | +73.1% | -26.8% | +4.1% |
| 2/14/2025 | AARD | $160K | -25.6% | -18.9% | +5.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| AARD | ▼ Sell | Open Market | 62,000 | $321K | 9/11/2026 | View on chart |
| AARD | ▼ Sell | Open Market | 14,754 | $74K | 9/10/2026 | View on chart |
| AARD | ▲ Buy | Open Market | 3,000 | $43K | 12/11/2025 | View on chart |
| AARD | ▲ Buy | Open Market | 6,000 | $48K | 9/9/2025 | View on chart |
| AARD | ▼ Sell | Other | 7,001 | — | 2/14/2025 | View on chart |
| AARD | ▲ Buy | Open Market | 10,000 | $160K | 2/14/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
RBC Capital Maintains Sector Perform Rating for Aardvark Therapeutics (AARD)
RBC Capital has reiterated a Sector Perform rating for Aardvark Therapeutics and kept its $6 price target unchanged. The update comes amid a broader view that the company remains a solid play within its therapeutic area. Analysts’ average target is $11.11, suggesting a potential upside if the stock moves toward its 52‑week high. The rating signals continued confidence in the company’s prospects without a change in the valuation outlook.
RBC Capital Maintains Sector Perform Rating for Aardvark Therapeutics (AARD). RBC Capital has reiterated a Sector Perform rating for Aardvark Therapeutics and kept its $6 price target unchanged. The update comes amid a broader view that the company remains a solid play within its therapeutic area. Analysts’ average target is $11.11, suggesting a potential upside if the stock moves toward its 52‑week high. The rating signals continued confidence in the company’s prospects without a change in the valuation outlook.